Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside
Ho, A, Wei, G, Maneval, E.C, Esquibel, V, Berger, M.F, Haque, S, Patel, R, Walsh, C, Hornby, Z, Multani, P, Li, G, Drilon, A
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy
Shah, N.J., Campbell, M.T., Mao, S., Ornstein, M.C., Haas, N.B., Gao, X., Hammers, H., Keshava-Prasad, H., Hoimes, C.J., Hussain, A., George, S., Gourdin, T.S., Nelson, A., Yan, H., Esquibel, V., McIntyre, G., Geller, R., Voss, M.H., Rini, B.I., Beckermann, K.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
8LBA - Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside
Ho, A., Wei, G., Maneval, E.C., Esquibel, V., Berger, M.F., Haque, S., Patel, R., Walsh, C., Hornby, Z., Multani, P., Li, G., Drilon, A.
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article